Uncategorised - European Medical Journal

Angiotensin Receptor Blockers May Worsen Coeliac Disease Outcomes

Findings indicated that patients taking ARBs had a higher likelihood of experiencing persistent symptoms and markers of poor small bowel healing.

COVID-19 Linked to Long-Term Connective Tissue Disorder Risks

The findings suggest that healthcare systems must prioritise post-COVID-19 care, with a focus on identifying and managing autoimmune and autoinflammatory disorders.

Inebilizumab Targets IgG4 Disease Flares

Inebilizumab, a CD19+ B-cell depleting therapy, can reduce flares and promote remission in patients with IgG4-related disease (IgG4-RD) according to the results of a new Phase III clinical trial.

Machine Learning Models Predict Success in Stopping Renal Replacement Therapy

Machine learning identifies key factors and predicts success in renal replacement therapy discontinuation for critically ill patients with acute kidney injury.

world in hands

Novartis takes the top spot in 2024 Access to Medicine Index

Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.

Rising Trends in Germline Genetic Testing for Prostate Cancer

Recent data shows a significant increase in germline genetic testing for prostate cancer, with a notable rise in urologist involvement.

Which Treatment for Malignant Pleural Effusions Works Best?

No difference in mortality found between indwelling pleural catheters and chemical pleurodesis for treating malignant pleural effusions.

New Study Evaluates VR/AR Headset Accuracy in Diagnosing Diverticulitis

VR/AR headsets could one day match desktops in diagnostic effectiveness, according to a recent study.

Meta-Analysis Reveals Impact of Hypotension on TBI Mortality

Patients with traumatic brain injury (TBI) and hypotension face doubled mortality odds, highlighting the need for precise blood pressure management in clinical practice.

Does Retreating Multiple Myeloma with Previously Refractory Drugs Work?

Patients with late line relapsed/refractory multiple myeloma (RRMM) could benefit from repeat treatment with drugs their disease has previously been refractory to.